{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:17:55Z","timestamp":1788351475389,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clcc.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:40Z","timestamp":1778760460000},"page":"360-369.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-0233","authenticated-orcid":false,"given":"Salvatore","family":"Corallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Agustoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Personeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Citterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2026.05.002_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA"},{"key":"10.1016\/j.clcc.2026.05.002_bib0002","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2026.05.002_bib0003","doi-asserted-by":"crossref","DOI":"10.3747\/co.26.4861","article-title":"A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada","volume":"26","author":"Kennecke","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0004","first-page":"135","article-title":"Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer","volume":"15","author":"McLean","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2026.05.002_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.019","article-title":"Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies","volume":"170","author":"Rossini","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2026.05.002_bib0006","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1200\/JCO.2015.61.2887","article-title":"Impact of subsequent therapies on outcome of the FIRE-3\/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer","volume":"33","author":"Modest","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0007","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.05.002_bib0008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0009","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double- blind, placebo- controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA Study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2026.05.002_bib0011","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2026.05.002_bib0012","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0013","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2026.05.002_bib0014","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2026.05.002_bib0016","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2026.05.002_bib0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2026.05.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","author":"Cremolini","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.annonc.2024.11.015","article-title":"Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO metastatic colorectal cancer living guideline","volume":"36","author":"Candia","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0020","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-17-3314","article-title":"A method to summarize toxicity in cancer randomized clinical trials","volume":"24","author":"Carbini","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2026.05.002_bib0021","unstructured":"National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2006. Available from: NCI CTEP CTCAE Resources."},{"key":"10.1016\/j.clcc.2026.05.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"JNCI"},{"key":"10.1016\/j.clcc.2026.05.002_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.12793\/tcp.2024.32.e15","article-title":"Exploration of pharmacokinetic differences between East Asians and Caucasians: insights from pharmacokinetic studies in healthy subjects","volume":"32","author":"Kim","year":"2024","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0024","unstructured":"National Cancer Institute (U.S.). Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE\u00ae) quick guide to the item library [Internet]. Bethesda (MD): National Institutes of Health; 2025. Available from: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/item-library.pdf."},{"key":"10.1016\/j.clcc.2026.05.002_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/oncolo\/oyad192","article-title":"The weighted toxicity score: confirmation of a simple metric to communicate toxicity in randomized trials of systemic cancer therapy","volume":"29","author":"Jordan","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2026.05.002_bib0026","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1158\/1078-0432.CCR-18-1562","article-title":"Advantages and adversities of the weighted toxicity score","volume":"24","author":"Vaishampayan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2026.05.002_bib0027","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/02841860510029662","article-title":"Capecitabine as third line therapy in patients with advanced colorectal cancer","volume":"44","author":"Gubanski","year":"2005","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.clcc.2026.05.002_bib0028","first-page":"2971","article-title":"The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience","volume":"31","author":"Saif","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2026.05.002_bib0029","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clinre.2013.11.006","article-title":"Raltitrexed-based chemotherapy for advanced colorectal cancer","volume":"38","author":"Liu","year":"2014","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/030089160609200404","article-title":"Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin","volume":"92","author":"Rimassa","year":"2006","journal-title":"Tumori"},{"key":"10.1016\/j.clcc.2026.05.002_bib0031","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ejca.2012.01.008","article-title":"A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer","volume":"48","author":"Ferrarotto","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2026.05.002_bib0032","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clcc.2026.05.002_bib0033","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Washington, DC: U.S. Department of Health and Human Services; 2017. Available from: cancer.gov."},{"issue":"10","key":"10.1016\/j.clcc.2026.05.002_bib0034","doi-asserted-by":"crossref","first-page":"djv216","DOI":"10.1093\/jnci\/djv216","article-title":"The imperative for a new approach to toxicity analysis in oncology clinical trials","volume":"107","author":"Thanarajasingam","year":"2015","journal-title":"JNCI"},{"key":"10.1016\/j.clcc.2026.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.1986.4.12.1772","article-title":"A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer","volume":"4","author":"Gelber","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0036","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.1989.7.1.36","article-title":"Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis","volume":"7","author":"Goldhirsch","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104297","article-title":"Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2","volume":"10","author":"Stintzing","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.clcc.2026.05.002_bib0038","article-title":"Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study","volume":"31","author":"Grothey","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.05.002_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:39:17Z","timestamp":1788349157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1533002826000289"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.05.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}